Mckesson (MCK) Stock
Major pharmaceutical distributor serving hospitals and pharmacies. Here's the price, business snapshot, and what's worth knowing about Mckesson in October 2026.
McKesson Corporation (ticker: MCK) is one of the world’s largest pharmaceutical distributors and healthcare services providers, supplying medicines, medical products and technology solutions to pharmacies, hospitals and manufacturers. With a market capitalisation of about $97.93B, McKesson operates a scale-driven business that benefits from recurring, high-volume flows but typically operates on thin distribution margins. Key investor considerations include exposure to the US healthcare system, sensitivity to drug pricing and reimbursement changes, ongoing regulatory and litigation risk, and the company’s push into specialty drugs, automation and software services that can lift profitability over time. McKesson historically generates significant cash flow and has returned capital to shareholders, but inventory- and working-capital intensity can create earnings volatility. This summary is for general, educational purposes only and not personal financial advice; values can fall as well as rise and suitability depends on individual circumstances.
Why It’s Moving
McKesson Shares Slip Amid Pre-Earnings Caution Despite Strong Long-Term AI and Specialty Growth Outlook
- Shares closed at $967.02, reflecting a -2.6% drop in the most recent session while the broader market gained, indicating specific weakness tied to pre-earnings sentiment.
- Analysts highlight that McKesson lacks the typical combination of factors required for an earnings beat in its upcoming report, prompting caution among momentum-focused traders.
- Despite near-term headwinds, the company’s specialty and oncology segment reported 41% year-over-year profit growth, supporting a thesis that AI adoption and FDA rare-disease drug approvals will drive future value.
McKesson Shares Slip Amid Pre-Earnings Caution Despite Strong Long-Term AI and Specialty Growth Outlook
- Shares closed at $967.02, reflecting a -2.6% drop in the most recent session while the broader market gained, indicating specific weakness tied to pre-earnings sentiment.
- Analysts highlight that McKesson lacks the typical combination of factors required for an earnings beat in its upcoming report, prompting caution among momentum-focused traders.
- Despite near-term headwinds, the company’s specialty and oncology segment reported 41% year-over-year profit growth, supporting a thesis that AI adoption and FDA rare-disease drug approvals will drive future value.
Sixth Month Growth Performance
When is the next earnings date for McKesson (MCK)?
McKesson Corporation has a confirmed upcoming earnings report scheduled for November 4, 2026, at 16:30 EST. This release will cover the company's fourth fiscal quarter results for the period ending in September 2026. Investors should note that this date follows the historical pattern of reporting approximately three months after the previous August announcement.
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying McKesson's stock, expecting its value to increase in the future.
Financial Health
McKesson is performing well with strong revenue and cash flow, despite a low profit margin.
Dividend
McKesson's low dividend yield of 0.34% indicates limited return through dividends. If you invested $1000 you would be paid $3.40 a year in dividends (based on the last 12 months).
Why You’ll Want to Watch This Stock
Scale & Reach
McKesson’s size delivers stable volumes and negotiating power, though low distribution margins mean scale doesn’t remove commercial or regulatory risk.
Technology Shift
Investment in automation and software could improve efficiency and margins over time, but returns depend on successful execution and adoption.
Policy & Regulation
Changes in drug pricing, reimbursement or legal outcomes can materially affect performance, so monitor regulatory developments closely.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
